11 Days
Source:
صحة
صحة
Ready to play
Ready to play
Bristol-Myers Squibb announced that their clinical trial of a new experimental drug, called Admiparant, showed promising results in slowing the decline of lung function in patients with idiopathic pulmonary fibrosis. The results indicated that the lower dose (60 milligrams) achieved a statistically significant benefit in reducing lung deterioration, while the higher dose (120 milligrams) showed improvement but without clear statistical significance. The drug works by inhibiting the "LPA1" protein, which is linked to the formation of fibrous tissue within the lungs, aiming to limit scarring and worsening fibrosis. Although the drug is still in phase three clinical trials and has not yet received regulatory approval, it represents an important step toward providing an effective treatment for idiopathic pulmonary fibrosis, with expectations of phase two trial results in early 2027.
Notice: This Is an AI-Generated Summary
Comments (0)